A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
Lantheus Holdings (NASDAQ:LNTH) plunged 20% and Point Biopharma (NASDAQ:PNT) fell 9% in premarket trading after the results of a Phase 3 readout for PNT2002, a lead candidate as a second-line option ...
BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- December 18, 2023 – Lantheus Holdings, Inc. (LNTH) (Lantheus) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced ...
Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results